

## Peer Review File

Article information: <https://dx.doi.org/10.21037/cco-23-33>

### Reviewer A

I reviewed the manuscript and I have the following comments.

Major comment:

1. Differences in treatment outcomes between China and others are not well understood by text. How do you prepare a table of trial outcomes?

*Thank you for your suggestion, a table containing the main outcomes of first-line immunotherapy from key phase III clinical trials were added in the manuscript in page 4, line 133.*

2. What does "Clinical and translational studies revealed the special biological behavior in Chinese GC patients" in introduction indicate?

*Chinese GC patients response differently to immunotherapy compared with global patients. For example, in GC immunotherapy, the results from checkmate-649 showed HR of 0.70 in CPS $\geq$ 5 population, while the subgroup-analysis of data from Chinese patients reported a HR of 0.56, the median PFS and OS were both longer than the global population, which indicate the higher sensitivity of Chinese GC patients to immunotherapy. The reason may be due to distinct genomic and TME features between the eastern and western world. Translational study revealed higher CD68/CD3 ratio in western GC patients, which correlated with worse survival. The reference was added right behind the sentence. Within Asian countries, however, the clinical data from Japan or Korea were also different from China.*

Minor comment:

3. "R&D" in abstract should not use abbreviations.

*R&D was replaced by "Research & development" in the abstract and marked in red.*

4. ADC on line 142 is the first one, so please write it in full spelling.

*Full spelling of antibody-drug conjugates was stated in the first ADC word place.*

### Reviewer B

98: "based on results" or "biasing results"? Which one did you intend?

*We intended to express the "based on results". We rephrase the word as "according to data from different clinical trials".*

144 define ADCC with first use

*ADCC means antibody-dependent cellular cytotoxicity, the detail was added.*

170: use "etc." over "et al."

*The mistake has been revised.*

188: Would more readers connect with the name "trastuzumab deruxtecan" than DS-8201, I suggest it be changed.

*DS-8201 was changed into trastuzumab deruxtecan and marked in red.*

**Reviewer C**

Accept